Search Results for "Colchicine And Rivaroxaban"

23:00 EDT 23rd May 2015 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

BRIEF-Hikma Pharma says preparing to distribute Colchicine

* Prepare to distribute its colchicine, which it will market under brand name mitigare

Takeda’s Take On Patent Certification Rules In Colchicine Dispute Rejected

A federal judge tosses Takeda’s suit against FDA, finding Hikma did not need to reference Takeda’s Colcrys or certify Colcrys patents to obtain approval of its colchicine product.

Hikma to launch colchicine in USA as Takeda’s injunction fails

Jordon-headquartered Hikma Pharmaceuticals saw its shares rise 4.2% to a record high of £23.80, after a USA appeals court rejected Japanese drug major Takeda Pharmaceutical’s bid to bock the firm...

Prasco to market authorized colchicine generic in the US

US generics maker, Prasco Laboratories (Prasco), announced on 12 January 2015 that it had entered into an alliance with the US subsidiary of Japanese pharmaceutical company, Takeda, to distribute an a...

Uninterrupted Rivaroxaban Feasible in AF Ablations, in Study

Event rates were low, but no major bleeding complications and no thromboembolic events occurred in the ablation group that had rivaroxaban maintained during the AF procedure. Heartwire from Meds...

Rivaroxaban vs Vitamin K Antagonists for Cardioversion in AF

Does oral rivaroxaban help to fast-track patients for cardioversion? European Heart Journal

Top stories in health and medicine, January 14, 2015

From MedPage Today: Carotid Stenting Linked to High Real-World Mortality. Carotid stenting was associated with much higher than expected 2-year mortality in the Medicare population. ‘Generic...

Antidote Reverses Anticoagulation Activity of Rivaroxaban: ANNEXA-R

The antidote immediately and significantly reversed the anticoagulation activity of rivaroxaban, making this study the second successful test of the antidote with the factor Xa inhibitors. Heart...

Matching PubMed Articles

Colchicine: Old and New.

Although colchicine has been a focus of research, debate and controversy for thousands of years, it was only approved by the United States Food and Drug Administration in 2009. Over the past decade, a...

Rivaroxaban does not impair fracture healing in a rat femur fracture model: an experimental study.

The prescription of the oral anticoagulant rivaroxaban to prevent thromboembolic episodes associated with orthopaedic surgery has dramatically increased since it was introduced. Rivaroxaban is beeing ...

Of men and meals.

Rivaroxaban is increasingly used to treat patients with acute venous thromboembolism (VTE), a potentially life-threatening condition. Since absorption of rivaroxaban decreases from nearly 100% to 66% ...

Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 - systematic review and meta-analysis.

The purpose of this study was to investigate and summarize available evidence on the efficacy and safety of colchicine for pericarditis prevention. Disease recurrence is the major and most common comp...

Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level:: The Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.

Rivaroxaban has become an alternative to vitamin-K antagonists (VKA) for stroke prevention in non-valvular atrial fibrillation (AF) patients due to its favourable risk-benefit profile in the restricti...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement